CN101664508A - Drug combination for treating centrality serous chorioretinitis - Google Patents
Drug combination for treating centrality serous chorioretinitis Download PDFInfo
- Publication number
- CN101664508A CN101664508A CN200910178026A CN200910178026A CN101664508A CN 101664508 A CN101664508 A CN 101664508A CN 200910178026 A CN200910178026 A CN 200910178026A CN 200910178026 A CN200910178026 A CN 200910178026A CN 101664508 A CN101664508 A CN 101664508A
- Authority
- CN
- China
- Prior art keywords
- blood
- drug combination
- radix
- centrality
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug combination for treating centrality serous chorioretinitis, composed of angelica, root of rehmannia, white paeony root, chrysanthemum, the rhizome of chuanxiong, savia miltiorrhiza, tuckahoe, rhizoma polygonati, white caltrop, semen cassiae and pearls. The drug combination has the efficacies of replenishing qi and nourishing blood, clearing heat and cooling blood, promoting blood circulation and removing blood stasis as well as removing nebula and improving eyesight, formula is scientific and curative effect is definite.
Description
Technical field:
The present invention relates to a kind of Chinese medicine composition, specifically a kind of pharmaceutical composition of therapeutic community's property serosity chorioretiniti.
Background technology:
Central serous chorioretinitis has another name called the vasospasm retinochoroiditis, is more common in youth and middle-aged male, mostly is simple eye morbidity, and tendency of recurrence is arranged.Pathogenic factor is still very not clear, it is generally acknowledged on the focal infection basis allergy takes place, and spastic contraction takes place blood vessel, causes local organization blood supply, oxygen supply obstacle, and vascular permeability increases, and forms macula lutea portion edema.Edema increases the weight of the local organization disturbance of blood circulation again, and blood capillary transfers expansion to, can cause hemorrhage and plasma fibrin exosmoses, cytophagous effect in organizing, and plasmocyte infiltrating is yellow-white or white point-like is oozed out.Psychentonia, excited, infection, allergy, vena chorioidea drain obstacle, thermal conditioning nonfunction all can inspire primary disease.General symptom mainly shows as central amblyopia, metamorphopsia, and patient is conscious to have a shadow in point of fixation central authorities, and gray or kermesinus are purple or green occasionally, as outbreak repeatedly, can leave over permanent visual disorder.Generally change the recovery stage over to through pathological changes after 1~3 month, edema and exudate absorb gradually, can not stay any vestige, but also can leave over irregular dirt shape pigmentation, and the central fovea luminous reflectance reappears, and vision improves or recovers fully.
Central serous chorioretinitis belongs to common retinopathy, can belong in the diseases such as " blurring of vission ", " optic atrohic blindness ", " chromatopsia ", " looking little anti-big ", " considering the straight line as the olbique due to visual distortion ", " considering the straight line as the curve due to metamorphopsia " of the traditional Chinese medical science.The traditional Chinese medical science thinks that this disease is many because of deficiency of the liver and kindey, eyes losing nutrition, dampness-heat of the liver, stagnation of QI-blood, or have dysfunction of the spleen in transportation concurrently, on the turbid damp general due to.
Because the cause of disease of primary disease, pathogenesis fail to understand still do not have special and effective Therapeutic Method a few days ago.Adopt treatment by Chinese herbs often comparatively effective, relevant Chinese medicinal formulae is existing to be used, but effect is desirable not enough, and therefore, the pharmaceutical composition that research has remarkable therapeutic community's property serosity chorioretiniti effect will show finer application prospect.
Summary of the invention:
At above-mentioned situation, the invention provides a kind of is the Chinese prescription of therapeutic community's property serosity chorioretiniti of purport with benefiting qi and nourishing blood, clearing away heat and cooling blood, activating blood circulation to dissipate blood stasis, and the technical scheme that the present invention takes is: a kind of pharmaceutical composition of therapeutic community's property serosity chorioretiniti, raw medicinal material by following weight is made: Radix Angelicae Sinensis 30g, Radix Rehmanniae 20g, Radix Paeoniae Alba 15g, Flos Chrysanthemi 12g, Rhizoma Chuanxiong 12g, Radix Salviae Miltiorrhizae 15g, Poria 15g, Rhizoma Polygonati 15g, Fructus Atriplicis Sibiricae 10g, Semen Cassiae 15g, Margarita 3g.
Preparation method: preferably make powder, medicinal ingredient is crushed and screened into does not carefully stir.Medicinal ingredient can also be cooperated medicine common formulations such as making capsule, tablet, pill, electuary, oral liquid with pharmaceutical carrier or additive.
Usage and dosage: oral powder one twice-daily, each 2g is grown up.
Function cures mainly: benefiting qi and nourishing blood, clearing away heat and cooling blood, activating blood circulation to dissipate blood stasis, remove nebula and make eye bright.Main therapeutic community's property serosity chorioretiniti.
Radix Angelicae Sinensis sweet in the mouth in the side and weighing specially can be enriched blood, and its gas is light and hot, thus again can promoting the circulation of blood, and invigorating middle warmer has, benefit is arranged in capable, is the key medicine in the blood; The Radix Rehmanniae has clearing away heat and cooling blood, YIN nourishing and the production of body fluid promoting effect, and the two specially takes charge of the QI and blood adjustment, and is monarch drug.
Borrow the Radix Paeoniae Alba suppressing liver-YANG in the side, nourish blood and receive merit, the heat clearing away of chrysanthemum powder forimproving wind of the moon, the effect that suppressing the hyperactive liver makes eye bright, regulating menstruation reason arteries and veins is the ministerial drug of side.
Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae are good at blood-activating and qi-promoting in the side, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle; Poria diuretic dissipating fluid-retention, spleen invigorating mind calming, Rhizoma Polygonati nourishing kidney profit spleen, invigorating the spleen and replenishing QI; Fructus Atriplicis Sibiricae suppressing the hyperactive liver resolving depression, dispelling pathogenic wind for improving eyesight; The Semen Cassiae liver heat removing and eyesight improving, the kind wind heat acute conjunctivitis, optic atrohic blindness nyctalopia controlled.All flavors are adjuvant drug altogether.
Margarita has more liver heat removing and removes the nebula special effect that makes eye bright in the side, is the messenger drug of side.
Full side is a purport with Radix Angelicae Sinensis, Radix Rehmanniae benefiting qi and nourishing blood, clearing away heat and cooling blood, minister is with Radix Paeoniae Alba, Flos Chrysanthemi,, wind heat clearing away diffusing from suppressing liver-YANG started with, assistant is carried out effects such as blood-activating and qi-promoting, stasis-dispelling and pain-killing, diuretic dissipating fluid-retention, nourishing kidney profit spleen, suppressing the hyperactive liver resolving depression, liver heat removing and eyesight improving with Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Poria, Rhizoma Polygonati, Fructus Atriplicis Sibiricae, Semen Cassiae, make at last to bring into play its liver heat removing with Margarita and remove the nebula speciality that makes eye bright.Full side's combination thinking is clear and definite, and compatibility brings out the best in each other, and plays benefiting qi and nourishing blood, clearing away heat and cooling blood, activating blood circulation to dissipate blood stasis altogether, removes the merit that nebula makes eye bright.
Beneficial effect:
1, prescription science meets differential diagnosis in tcm and executes the improvement opinion, the whole paathogenic factor of considering central serous chorioretinitis, the pharmacodynamic feature and the synergism of integrated use and performance prescription medicine.
2, determined curative effect can make the optical fundus edema effectively and ooze out absorption and accelerate, and complication and sequela minimizing, and visual function recovers better, through clinical 67 routine diseases is carried out the systematic treating observation, and total effective rate 97.01% is wherein cured 55 examples, accounts for 82.11%; Produce effects 10 examples account for 14.9%; Invalid 2 examples account for 2.99%.
3, property of medicine gentleness does not have bad reflection, has no side effect.
The specific embodiment:
The present invention will be further described below in conjunction with embodiment:
Embodiment 1:
Get the raw medicinal material of following weight: Radix Angelicae Sinensis 30g, Radix Rehmanniae 20g, Radix Paeoniae Alba 15g, Flos Chrysanthemi 12g, Rhizoma Chuanxiong 12g, Radix Salviae Miltiorrhizae 15g, Poria 15g, Rhizoma Polygonati 15g, Fructus Atriplicis Sibiricae 10g, Semen Cassiae 15g, Margarita 3g.
Medicinal ingredient is crushed and screened into carefully do not stir.
Usage and dosage: an oral twice-daily, adult 2g, 7 days was 1 course of treatment.
Clinical diagnosis: visual deterioration, generally be not less than 0.2, the reflective wheel around the shadow at the moment, macula lutea, the reflective disappearance of central fovea has point-like exudate matter; The optical fundus radiography has the fluorescein seepage.
Among the 67 routine embodiment, male 49 examples, women 18 examples; 32 ~ 48 years old age; The shortest person of disease time 1 day, elder 12 days.
55 examples are cured in the treatment of employing said method, and effective percentage is 82.11%.Wherein cure 21 examples 2 courses of treatment, cure 29 examples 3 courses of treatment, cure 5 examples 4 courses of treatment.
Criterion of cure: subjective symptoms disappears, naked vision or correct defects of vision>5.0, or return to the premorbid level, and macular edema disappears, and exudate absorbs, and leaves over a small amount of old exudate and absorbs the back cicatrix, and as seen central fovea reflective.
Produce effects 10 examples, effective percentage are 14.9%.Wherein 2 the course of treatment produce effects 4 examples, 3 the course of treatment produce effects 2 examples, 4 the course of treatment produce effects 4 examples.
The produce effects standard: subjective symptoms disappears substantially, and vision improves, and exudate obviously absorbs, the reflective disperse of central fovea.
Invalid 2 examples account for 2.99%.
Invalid standard: vision does not improve, and macular area improves not obvious.
Above-mentioned case was followed up a case by regular visits to 1 year, cure case and recur 3 examples.Cure after the recurrence case history used 4 courses of treatment of above-mentioned treatment by Chinese herbs.
Claims (1)
1, a kind of pharmaceutical composition of therapeutic community's property serosity chorioretiniti is made up of following materials of weight proportions medical material: Radix Angelicae Sinensis 30g, Radix Rehmanniae 20g, Radix Paeoniae Alba 15g, Flos Chrysanthemi 12g, Rhizoma Chuanxiong 12g, Radix Salviae Miltiorrhizae 15g, Poria 15g, Rhizoma Polygonati 15g, Fructus Atriplicis Sibiricae 10g, Semen Cassiae 15g, Margarita 3g.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101780264A CN101664508B (en) | 2009-09-18 | 2009-09-18 | Drug combination for treating centrality serous chorioretinitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101780264A CN101664508B (en) | 2009-09-18 | 2009-09-18 | Drug combination for treating centrality serous chorioretinitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101664508A true CN101664508A (en) | 2010-03-10 |
CN101664508B CN101664508B (en) | 2011-02-02 |
Family
ID=41801390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101780264A Expired - Fee Related CN101664508B (en) | 2009-09-18 | 2009-09-18 | Drug combination for treating centrality serous chorioretinitis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101664508B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103301267A (en) * | 2013-07-07 | 2013-09-18 | 崔新明 | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof |
CN105267466A (en) * | 2015-10-30 | 2016-01-27 | 方心淳 | Traditional Chinese medicine composition for treating retinitis |
CN105288355A (en) * | 2015-10-30 | 2016-02-03 | 程素芹 | Traditional Chinese medicine preparation for treating central retinitis |
-
2009
- 2009-09-18 CN CN2009101780264A patent/CN101664508B/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103301267A (en) * | 2013-07-07 | 2013-09-18 | 崔新明 | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof |
CN103301267B (en) * | 2013-07-07 | 2014-11-05 | 崔新明 | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof |
CN105267466A (en) * | 2015-10-30 | 2016-01-27 | 方心淳 | Traditional Chinese medicine composition for treating retinitis |
CN105288355A (en) * | 2015-10-30 | 2016-02-03 | 程素芹 | Traditional Chinese medicine preparation for treating central retinitis |
Also Published As
Publication number | Publication date |
---|---|
CN101664508B (en) | 2011-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102166278B (en) | Chinese medicinal composition for treating pediatric rheumatoid arthritis and preparation method thereof | |
CN102920794A (en) | Traditional Chinese medicine for treating rhinitis | |
CN101954028A (en) | Medicinal pillow for preventing and treating myopic eyes | |
CN103223118A (en) | Traditional Chinese medicine composition for treating facial paralysis | |
CN102274385B (en) | Medicament for treating nasosinusitis and preparation method thereof | |
CN101664508B (en) | Drug combination for treating centrality serous chorioretinitis | |
CN102670993B (en) | Traditional Chinese medicine for treating cataract | |
CN103211962B (en) | Chinese medicinal composition for treating anhypnia | |
CN103550549B (en) | A kind of Chinese medicine composition for the treatment of deficiency of heart-yin | |
CN102416145A (en) | Chinese medicinal composition for treating menstrual disorder | |
CN102389488A (en) | Traditional Chinese medicine for curing diabetic retinopathy | |
CN104606635A (en) | Traditional Chinese medicine composition for treating retinal vein obstruction | |
CN102379967A (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
CN102228670B (en) | Traditional Chinese medicine for treating postoperative scar pain | |
CN104116983A (en) | Oral liquid for preventing puerperal fever | |
CN102389485A (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
CN102389487A (en) | Traditional Chinese medicine for curing diabetic retinopathy | |
CN104491403A (en) | Medicine for treating central retinochoroiditis and preparation method | |
CN101147763A (en) | Orally-administered medicine for treating chloasma | |
CN105106805A (en) | Traditional Chinese medicine combination for treating insomnia | |
CN102698127B (en) | Traditional Chinese medicine for treating infantile diarrhea | |
CN103860899B (en) | A kind of Chinese medicine composition treating diabetic foot | |
CN104288604A (en) | Traditional Chinese medicine composition for treating cerebral infarction | |
CN104013831A (en) | Medicament for treating insufficient blood supply | |
CN102670827A (en) | Chinese medicine for treating diabetic retinopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110202 Termination date: 20110918 |